Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Strategies to Optimize the Utilization of Stored Autologous Peripheral Blood Stem Cells for Second Transplantation in Multiple Myeloma

Amany R. Keruakous, Laura Walker, Molly James, Anand P. Jillella, Mohammad A.H. Mian, Vamsi K. Kota, Danielle Bradshaw

Blood (2022) 140 (Supplement 1): 4701–4702.

https://doi.org/10.1182/blood-2022-159763

Published: 2022

Journal Articles

Optical Genome Mapping and Comprehensive Next Generation Sequencing Panel for Myeloid Cancers: New Era of Complimentary Profiling

Nikhil Sahajpal, Ashis Mondal, Anand P. Jillella, Vamsi Kota, Ravindra Kolhe

Blood (2022) 140 (Supplement 1): 9175–9176.

https://doi.org/10.1182/blood-2022-170638

Published: 2022

Journal Articles

Unraveling Gene Fusions with Optical Genome Mapping in Hematological Malignancies: The Unexplored Terrain

Nikhil Sahajpal, Vamsi K. Kota, Anand P. Jillella, Ashis Mondal, Ravindra Kolhe

Blood (2022) 140 (Supplement 1): 11478–11479.

https://doi.org/10.1182/blood-2022-170625

Published: 2022

Journal Articles

Homologous Recombination Deficiency (HRD) in Hematological Malignancies

Nikhil Sahajpal, Vamsi K. Kota, Anand P. Jillella, Ashis Mondal, Ravindra Kolhe

Blood (2022) 140 (Supplement 1): 11839–11840.

https://doi.org/10.1182/blood-2022-170583

Published: 2022

Journal Articles

Incremental Clinically Relevant Information in 70 CLL Cases with Optical Genome Mapping: Going Beyond Karyotype and FISH

Nikhil Sahajpal, Anand P. Jillella, Ashis Mondal, Harmanpreet Singh, Ashutosh Vashisht, Huidong Shi, Vamsi K. Kota, Ravindra Kolhe

Blood (2022) 140 (Supplement 1): 12361–12362.

https://doi.org/10.1182/blood-2022-168454

Published: 2022

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Sandeep Anand Padala, Anusha Vakiti, Wendy Bollag, Jennifer Waller, Mufaddal Kheda, Stephanie L Baer, Ravindra Kolhe, Mohammad A.H. Mian, Anand P. Jillella, Jorge E. Cortes, Vamsi Kota

Blood (2022) 140 (Supplement 1): 7697–7698.

https://doi.org/10.1182/blood-2022-170672

Published: 2022

Journal Articles

Impact of Qualified Dedicated APL Leukemia Specialist and Simplified Treatment Algorithm on Early Deaths in APL, a Monocenter Experience

Michal Jakub Kubiak, Anand P. Jillella, Danielle Bradshaw, Natasha M. Savage, Locke J. Bryan, Ravindra Kolhe, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 6108–6109.

https://doi.org/10.1182/blood-2022-168155

Published: 2022

Journal Articles

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Anand P. Jillella, Sandra J. Lee, Jessica K. Altman, Selina M. Luger, Martin S. Tallman, James M. Foran, Lisa Y. Law, Locke J. Bryan, Abdallah Abou Zahr, Kebede Begna, Alexander Perl, Joseph Vadakara, Federico Sanchez, Raymond C. Bergan, Michael J. Fisch, Ruth C. Carlos, Lynne I. Wagner, Mark R. Litzow, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 1011–1013.

https://doi.org/10.1182/blood-2022-163436

Published: 2022

Journal Articles

Musculoskeletal Pain Syndrome in a Subset of APL Patients during Induction Therapy

Michal Jakub Kubiak, Anand P. Jillella, Danielle Bradshaw, Natasha M. Savage, Ravindra Kolhe, Locke J. Bryan, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 8948–8949.

https://doi.org/10.1182/blood-2022-168090

Published: 2022

Journal Articles

Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized By Dizziness, Orthostatic Hypotension, and Weight Loss

Anand P. Jillella, Irina Shishkina, Gita Giddens, Courtney Corley, Kimberly Green, Rachel Ashley, Megan Johnson, Laura Walker, Sarah Jimenez, Locke J. Bryan, Ayushi Chauhan, Amany R. Keruakous, Molly James, Mohammad A.H. Mian, Danielle Bradshaw, Ravindra Kolhe, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 12547–12548.

https://doi.org/10.1182/blood-2022-166437

Published: 2022

Journal Articles

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Zachery Clint Branham, Chijioke Okereke, Mahran Shoukier, Danielle Bradshaw, Ravindra Kolhe, Anand P. Jillella, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 8929.

https://doi.org/10.1182/blood-2022-164963

Published: 2022

Journal Articles

Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access

Sujith Abbagoni, Sarah Malik, Ashley D Fox, Mohammad A. H. Mian, Tahsin Anwar, Danielle Bradshaw, Locke J. Bryan, Anand P Jillella, Ravindra Kolhe, Natasha M. Savage, Sandeep Padala, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4953.

https://doi.org/10.1182/blood-2021-154465

Published: 2021

Journal Articles

The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients

Chijioke Okereke, Ashley D Fox, Thuy Le, Sujith Abbagoni, Anand P Jillella, Locke J. Bryan, Tahsin Anwar, Mohammad A. H. Mian, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2021-154312

Published: 2021

Journal Articles

Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting

Sujith Abbagoni, Thuy Le, Locke J. Bryan, Mohammad A. H. Mian, Danielle Bradshaw, Ashley D Fox, Anand P Jillella, Chijioke Okereke, Ravindra Kolhe, Natasha M. Savage, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2021-154524

Published: 2021

Journal Articles

Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML)

Ashley D Fox, Chijioke Okereke, Thuy Le, Anand P Jillella, Locke J. Bryan, Tahsin Anwar, Mohammad A. H. Mian, Danielle Bradshaw, Ravindra Kolhe, Natasha M. Savage, Germame Ajebo, Sandeep Padala, Sujith Abbagoni, Vamsi Kota

Blood (2021) 138 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2021-154138

Published: 2021

Journal Articles

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Tahsin Anwar, Mohammed Mian, Mahran Shoukier, Achuta K Guddati, Moinul Hossain, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD, Vamsi Kota, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143329

Published: 2020

Journal Articles

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Mahran Shoukier, Vamsi Kota, MD, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-135940

Published: 2020

Journal Articles

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Eytan M. Stein, Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E. Lancet, Farhad Ravandi, Tibor Kovacsovics, Daniel J. DeAngelo, Dale Bixby, Stefan Faderl, Anand P. Jillella, Phoenix A. Ho, Megan M. O’Meara, Baiteng Zhao, Charles Biddle-Snead, Anthony S. Stein

Blood (2018) 131 (4): 387–396.

https://doi.org/10.1182/blood-2017-06-789800

Published: 2018

Includes: Supplemental data

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

NARROW

Strategies to Optimize the Utilization of Stored Autologous Peripheral Blood Stem Cells for Second Transplantation in Multiple Myeloma

Optical Genome Mapping and Comprehensive Next Generation Sequencing Panel for Myeloid Cancers: New Era of Complimentary Profiling

Unraveling Gene Fusions with Optical Genome Mapping in Hematological Malignancies: The Unexplored Terrain

Homologous Recombination Deficiency (HRD) in Hematological Malignancies

Incremental Clinically Relevant Information in 70 CLL Cases with Optical Genome Mapping: Going Beyond Karyotype and FISH

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Impact of Qualified Dedicated APL Leukemia Specialist and Simplified Treatment Algorithm on Early Deaths in APL, a Monocenter Experience

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Musculoskeletal Pain Syndrome in a Subset of APL Patients during Induction Therapy

Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized By Dizziness, Orthostatic Hypotension, and Weight Loss

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access

The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients

Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting

Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML)

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only